Bayer AG ((BAYRY)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: Bayer AG, in collaboration with AskBio Inc, is conducting a Phase 2 clinical study titled ‘A Study of AAV2-GDNF in Adults With Moderate Parkinson’s Disease (REGENERATE-PD)’. The study aims to assess the safety and efficacy of AAV2-GDNF gene therapy delivered to the putamen in individuals with moderate Parkinson’s Disease. This research is significant as it explores a potential new treatment avenue for Parkinson’s, which could improve the quality of life for patients.
Intervention/Treatment: The study tests an experimental gene therapy called AAV2-GDNF. This treatment involves a bilateral image-guided infusion of the gene therapy into the putamen, aiming to provide therapeutic benefits for Parkinson’s patients. A control group undergoes a sham surgery for comparison.
Study Design: This interventional study is randomized and employs a parallel assignment model. It features quadruple masking, meaning that participants, care providers, investigators, and outcomes assessors are blinded to the treatment allocation. The primary purpose is to evaluate the treatment’s efficacy and safety.
Study Timeline: The study began on February 14, 2024, and is currently recruiting participants. The last update was submitted on August 25, 2025, indicating ongoing progress. These dates are crucial for tracking the study’s development and potential future findings.
Market Implications: The update on this study could positively influence Bayer’s stock performance by showcasing its commitment to innovative treatments in the neurological field. Successful outcomes could enhance investor sentiment and position Bayer competitively within the pharmaceutical industry, especially against other companies exploring Parkinson’s treatments.
The study is ongoing, with further details available on the ClinicalTrials portal.